Dr Christopher Evans provided an extraordinary level of care by recognizing that my body was able to benefit from a prostatectomy to treat my prostate cancer, even though I was at an upper age limit for the procedure. As proof of his correct assessment, I have had a remarkably good recovery since the operation was performed last December, giving me another lease on life. I climbed Kilimanjaro on August 28th without any ill effects
Meet the Provider
Affiliated Groups
Specialties
- Urology Oncology
Areas of Expertise
- Urology
- Kidney Cancer
- Prostate Cancer
- Bladder Cancer
- Testicular Cancer
Locations
Languages Spoken
- English
- German
Education
Medical School • 1986
Dartmouth Medical School
Fellowship • 1994
National Kidney Foundation
Research Scholar Fellowship
Residency • 1995
University of California, San Francisco
Urology
Fellowship • 1997
University of Texas M.D. Anderson Cancer Center
Urologic Surgical Oncology
Research Interests
- Multimodal mechanisms to treat high risk prostate cancer. The PROTEUS trial was published in the New England Journal of Medicine June, 2026.
Publications
- Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
- Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.
- Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.
- Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.
- Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.
- IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer.
- The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
- Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
- The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
- Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review.
- Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
- Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
- Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
- ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
- Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
- The DNA methylation landscape of advanced prostate cancer.
- Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.